Genmab Feed

Land	Danmark
Lista	Large Cap Copenhagen
Sektor	Hälsovård
Industri	Bioteknik

2023-11-27 13:00:00 Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma -3,10% | 386 MDKK

2023-11-21 22:45:58 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +0,28% | 121 MDKK

2023-11-21 22:42:23 Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab +0,28% | 121 MDKK

2023-11-09 15:14:35 Major Shareholder Announcement +0,78% | 342 MDKK

2023-11-09 11:00:00 Genmab to Present at Jefferies London Healthcare Conference +0,78% | 342 MDKK

2023-11-08 17:09:05 Major Shareholder Announcement +0,78% | 342 MDKK

2023-11-07 17:01:39 Genmab Announces Financial Results for the First Nine Months of 2023 +7,13% | 619 MDKK

2023-11-02 14:05:00 Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) -3,61% | 697 MDKK

2023-10-22 16:30:00 TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial +0,44% | 226 MDKK

2023-10-17 12:22:45 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023 +1,11% | 311 MDKK

2023-09-28 20:38:56 Grant of Restricted Stock Units and Warrants to Employees in Genmab +0,68% | 216 MDKK

2023-09-25 13:45:00 Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) -0,32% | 149 MDKK

2023-09-25 11:55:00 EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) -0,32% | 149 MDKK

2023-09-12 20:04:15 Capital Increase in Genmab as a Result of Employee Warrant Exercise -0,63% | 178 MDKK

2023-09-04 21:00:00 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy -0,11% | 193 MDKK

2023-08-28 16:06:30 Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference +2,22% | 137 MDKK

2023-08-15 19:09:52 Capital Increase in Genmab as a Result of Employee Warrant Exercise -0,59% | 164 MDKK

2023-08-03 17:01:37 Genmab Announces Financial Results for the First Half of 2023 -3,80% | 362 MDKK

2023-07-28 00:01:26 Genmab Updates 2023 Financial Guidance +2,13% | 193 MDKK

2023-07-21 10:30:00 Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) +0,54% | 185 MDKK

2023-07-20 12:22:48 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023 +1,91% | 245 MDKK

2023-06-28 00:49:00 Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) -1,73% | 164 MDKK

2023-06-22 13:00:00 Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’ +1,01% | 174 MDKK

2023-06-20 20:45:10 Capital Increase in Genmab as a Result of Employee Warrant Exercise -1,26% | 200 MDKK

2023-06-09 09:01:00 Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 -0,45% | 133 MDKK

2023-06-08 23:22:22 Grant of Restricted Stock Units and Warrants to Employees in Genmab -0,45% | 133 MDKK

2023-06-06 08:00:00 Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference +0,77% | 210 MDKK

2023-06-01 21:40:56 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -0,48% | 271 MDKK

2023-05-31 14:15:21 Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons -0,76% | 675 MDKK

2023-05-25 23:10:00 Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress -0,11% | 103 MDKK

2023-05-23 21:14:54 Capital Increase in Genmab as a Result of Employee Warrant Exercise -2,07% | 214 MDKK

2023-05-19 18:33:00 EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) +3,19% | 342 MDKK

2023-05-10 17:01:38 Genmab Announces Financial Results for the First Quarter of 2023 +4,98% | 609 MDKK

2023-04-24 10:39:33 Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen +0,54% | 181 MDKK

2023-04-21 01:45:24 Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen +0,32% | 203 MDKK

2023-04-18 12:25:45 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023 -2,75% | 547 MDKK

2023-04-17 08:00:00 Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology +3,12% | 378 MDKK

2023-04-06 22:33:03 Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons +1,22% | 262 MDKK

2023-04-03 22:30:18 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +0,16% | 196 MDKK

2023-04-03 16:12:34 Completion of share buy-back program -1,27% | 204 MDKK

2023-03-29 22:19:26 Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons -0,85% | 215 MDKK

2023-03-29 22:10:26 Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab -0,85% | 215 MDKK

2023-03-29 15:54:01 Passing of Genmab A/S’ Annual General Meeting +0,70% | 187 MDKK

2023-03-28 08:00:00 Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer -1,08% | 230 MDKK

2023-03-27 15:00:46 Transactions in connection with share buy-back program +1,01% | 237 MDKK

2023-03-20 15:21:11 Transactions in connection with share buy-back program -0,40% | 184 MDKK

2023-03-13 14:41:08 Transactions in connection with share buy-back program +1,18% | 343 MDKK

2023-03-13 12:18:33 Transactions in connection with share buy-back program +1,18% | 343 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2024-11-06	Kvartalsrapport 2024-Q3
2024-08-01	Kvartalsrapport 2024-Q2
2024-05-02	Kvartalsrapport 2024-Q1
2024-03-13	Årsstämma 2024
2024-02-14	Bokslutskommuniké 2023
2023-11-07	Kvartalsrapport 2023-Q3
2023-08-03	Kvartalsrapport 2023-Q2
2023-05-10	Kvartalsrapport 2023-Q1
2023-03-30	Ordinarie utdelning GMAB 0.00 DKK
2023-03-29	Årsstämma 2023
2023-02-22	Bokslutskommuniké 2022
2022-11-09	Kvartalsrapport 2022-Q3
2022-08-10	Kvartalsrapport 2022-Q2
2022-05-11	Kvartalsrapport 2022-Q1
2022-03-30	Ordinarie utdelning GMAB 0.00 DKK
2022-03-29	Årsstämma 2022
2022-02-16	Bokslutskommuniké 2021
2021-11-10	Kvartalsrapport 2021-Q3
2021-08-11	Kvartalsrapport 2021-Q2
2021-05-05	Kvartalsrapport 2021-Q1
2021-04-14	Ordinarie utdelning GMAB 0.00 DKK
2021-04-13	Årsstämma 2021
2021-02-23	Bokslutskommuniké 2020
2020-11-04	Kvartalsrapport 2020-Q3
2020-08-12	Kvartalsrapport 2020-Q2
2020-05-06	Kvartalsrapport 2020-Q1
2020-03-27	Ordinarie utdelning GMAB 0.00 DKK
2020-03-26	Årsstämma 2020
2020-02-19	Bokslutskommuniké 2019
2019-04-01	Ordinarie utdelning GMAB 0.00 DKK
2019-03-29	Årsstämma 2019
2018-11-14	Kvartalsrapport 2018-Q3
2018-08-08	Kvartalsrapport 2018-Q2
2018-05-08	Kvartalsrapport 2018-Q1
2018-04-11	Ordinarie utdelning GMAB 0.00 DKK
2018-04-10	Årsstämma 2018
2018-02-21	Bokslutskommuniké 2017
2017-11-08	Kvartalsrapport 2017-Q3
2017-08-09	Kvartalsrapport 2017-Q2
2017-05-10	Kvartalsrapport 2017-Q1
2017-03-29	Ordinarie utdelning GMAB 0.00 DKK
2017-03-28	Årsstämma 2017
2017-02-22	Bokslutskommuniké 2016
2016-11-10	Kapitalmarknadsdag 2016
2016-11-02	Kvartalsrapport 2016-Q3
2016-08-09	Kvartalsrapport 2016-Q2
2016-05-10	Kvartalsrapport 2016-Q1
2016-03-18	Ordinarie utdelning GMAB 0.00 DKK
2016-03-17	Årsstämma 2016
2016-02-17	Bokslutskommuniké 2015
2015-11-03	Kvartalsrapport 2015-Q3
2015-08-11	Kvartalsrapport 2015-Q2
2015-05-12	Kvartalsrapport 2015-Q1
2015-03-27	Ordinarie utdelning GMAB 0.00 DKK
2015-03-26	Årsstämma 2015
2015-03-02	Bokslutskommuniké 2014
2014-11-05	Kvartalsrapport 2014-Q3
2014-08-13	Kvartalsrapport 2014-Q2
2014-05-07	Kvartalsrapport 2014-Q1
2014-04-10	Ordinarie utdelning GMAB 0.00 DKK
2014-04-09	Årsstämma 2014
2014-03-04	Bokslutskommuniké 2013
2013-11-06	Kvartalsrapport 2013-Q3
2013-08-14	Kvartalsrapport 2013-Q2
2013-05-07	Kvartalsrapport 2013-Q1
2013-04-18	Ordinarie utdelning GMAB 0.00 DKK
2013-04-17	Årsstämma 2013
2013-03-07	Bokslutskommuniké 2012
2012-11-07	Kvartalsrapport 2012-Q3
2012-08-15	Kvartalsrapport 2012-Q2
2012-05-09	Kvartalsrapport 2012-Q1
2012-04-26	Ordinarie utdelning GMAB 0.00 DKK
2012-04-25	Årsstämma 2012
2011-11-02	Kvartalsrapport 2011-Q3
2011-08-03	Kvartalsrapport 2011-Q2
2011-05-11	Kvartalsrapport 2011-Q1
2011-04-07	Ordinarie utdelning GMAB 0.00 DKK
2011-04-06	Årsstämma 2011
2011-02-28	Bokslutskommuniké 2010
2010-04-22	Ordinarie utdelning GMAB 0.00 DKK

Genmab

Kalender

Beskrivning

Genmab

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden